• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

FDA-TRACK

The list below provides information on FDA’s performance measures and projects as aligned to FDA strategic priorities and program offices. This list enables you to view charts of performance data and progress on important projects and programs.

To view completed FDA-TRACK performance measures and projects view the Archive Index

Filter








Results

Number of results: 13

ItemProgramOfficeStrategic PlanStrategic Goal/Area
1Cumulative percentage of IDE studies with full approval in two review cycles or lessCDRHAllCDRH Strategic PlanStrengthen the Clinical Trial Enterprise
2Percent of meeting offerings made within 10 days of IDE study disapproval decisionCDRHAllCDRH Strategic PlanStrengthen the Clinical Trial Enterprise
3Median number of days between receipt of IDE study and granting full approval decisions during the monthCDRHAllCDRH Strategic PlanStrengthen the Clinical Trial Enterprise
4Cumulative percentage of device types/product codes evaluatedCDRHAllCDRH Strategic PlanStrike the Right Balance Between Premarket and Postmarket Data Collection
5Percent of CDRH FY14 Receipt Cohort Real Time PMA Supplements MDUFMA decision made in 90 days or less during the quarterCDRHAllCDRH Strategic PlanStrike the Right Balance Between Premarket and Postmarket Data Collection
6Percent of CDRH FY14 Receipt Cohort 510(k) decisions meeting MDUFMA performance goals during the quarterCDRHAllCDRH Strategic PlanStrike the Right Balance Between Premarket and Postmarket Data Collection
7Percent of death MDRs reviewed within 5 business daysCDRHAllCDRH Strategic PlanStrike the Right Balance Between Premarket and Postmarket Data Collection
8 Percent of "Code Blue" MDRs reviewed within 72 hoursCDRHAllCDRH Strategic PlanStrike the Right Balance Between Premarket and Postmarket Data Collection
9Number of OSEL-generated research papers about medical device related issues published during the monthCDRHAllCDRH Strategic PlanStrike the Right Balance Between Premarket and Postmarket Data Collection
10Number of scientific and technical training classes and presentations (internal and external) by OSEL staff during the monthCDRHAllCDRH Strategic PlanStrike the Right Balance Between Premarket and Postmarket Data Collection
11Number of technical reviews of new applications and data supporting requests for premarket approvals completed during the monthCDRHAllCDRH Strategic PlanStrike the Right Balance Between Premarket and Postmarket Data Collection
12Number of scientific consults completed for various postmarket regulatory processesCDRHAllCDRH Strategic PlanStrike the Right Balance Between Premarket and Postmarket Data Collection
13Cumulative percent of satisfied customers at the end of the monthCDRHAllCDRH Strategic PlanProvide Excellent Customer Service

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information in the Archive Index may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.